{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:08:37Z","timestamp":1779322117903,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce cardiovascular events across a wide range of kidney function, including advanced stages of chronic kidney disease, but evidence for their efficacy in patients with kidney failure on haemodialysis is lacking. The underlying mechanisms remain incompletely understood, and whether cardiovascular benefits depend on residual kidney function is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>The Dapagliflozin in Hemodialysis (DAPA-HD) trial (NCT05179668) is an academic, multicentre, randomized, double-blind, placebo-controlled trial designed to assess the cardiovascular effects of dapagliflozin in 220 patients with kidney failure receiving haemodialysis. Stratified block randomization was based on patient-reported residual urine volume. The primary endpoint is the change in left ventricular mass indexed to body surface area using echocardiography after 6 months of treatment. A prespecified subgroup analysis will compare treatment effects between patients with residual urine output &amp;gt;200\u2005ml\/24\u2005h versus \u2264200\u2005ml\/24\u2005h. Secondary endpoints include additional echocardiographic assessments, changes in biomarker concentrations, quality of life, and clinical events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The DAPA-HD trial is the first trial specifically evaluating the cardiovascular and haemodynamic effects of dapagliflozin in patients with kidney failure receiving maintenance haemodialysis with and without residual urine outputs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag104","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:36:40Z","timestamp":1775561800000},"source":"Crossref","is-referenced-by-count":0,"title":["Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-8598","authenticated-orcid":false,"given":"Thomas A","family":"Zelniker","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Paschen","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mann","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Eigner","sequence":"additional","affiliation":[{"name":"Favoriten Hospital (Klinik Favoriten, 1st Medical Department) , Kundratsgasse 3, Wien 1100 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hildegard","family":"Hafner-Gie\u00dfauf","sequence":"additional","affiliation":[{"name":"Dialyseinstitut Gie\u00dfauf GmbH , Elisabethstra\u00dfe 54, Graz 8010 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kletzmayr","sequence":"additional","affiliation":[{"name":"Donaustadt Hospital (Klinik Donaustadt, 3rd Medical Department) , Langobardenstra\u00dfe 122, Vienna 1220 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Wiener Dialysezentrum , Kapellenweg 37, Vienna 1220 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[{"name":"1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolism, Landstrasse Clinic , Juchgasse 25, Vienna 1030 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stulnig","sequence":"additional","affiliation":[{"name":"Department of Medicine III and Karl Landsteiner Institute for Metabolic Diseases and Nephrology , Clinic Hietzing, Wolkersbergenstrasse 1, Vienna 1130 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar","family":"Waller","sequence":"additional","affiliation":[{"name":"Dialyseinstitut Dr. Waller , Feldgasse 28\u201330, Feldbach 8330 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Werzowa","sequence":"additional","affiliation":[{"name":"Hanusch Hospital (Hanusch-Krankenhaus, 1st Medical Department) , Heinrich-Collin-Stra\u00dfe 30, Vienna 1140 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"H\u00f6dlmoser","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-2994","authenticated-orcid":false,"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-6275","authenticated-orcid":false,"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-2395","authenticated-orcid":false,"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026052019382076500_xvag104-B1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2026052019382076500_xvag104-B2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026052019382076500_xvag104-B3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/jama.2024.16338","article-title":"Dialysis for chronic kidney failure: a review","volume":"332","author":"Flythe","year":"2024","journal-title":"JAMA"},{"key":"2026052019382076500_xvag104-B4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(16)30508-6","article-title":"The heart and vascular system in dialysis","volume":"388","author":"Wanner","year":"2016","journal-title":"Lancet"},{"key":"2026052019382076500_xvag104-B5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/CIRCRESAHA.122.321748","article-title":"The cardio-kidney patient: epidemiology, clinical characteristics and therapy","volume":"132","author":"Schuett","year":"2023","journal-title":"Circ Res"},{"key":"2026052019382076500_xvag104-B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026052019382076500_xvag104-B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"2026052019382076500_xvag104-B8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2026052019382076500_xvag104-B9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF Randomized Clinical Trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026052019382076500_xvag104-B10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026052019382076500_xvag104-B12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.ajkd.2019.02.012","article-title":"Self-reported urine volume in hemodialysis patients: predictors and mortality outcomes in the international Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"74","author":"Hecking","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026052019382076500_xvag104-B13","author":"Hays"},{"key":"2026052019382076500_xvag104-B14","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s40620-025-02434-y","article-title":"Hemodynamic effects of hemodialysis: the interaction between the heart and the arteries","volume":"38","author":"Mustafa","year":"2025","journal-title":"J Nephrol"},{"key":"2026052019382076500_xvag104-B15","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000001088","article-title":"Cardiovascular effects of home dialysis therapies: a scientific statement from the American Heart Association","volume":"146","author":"Sarnak","year":"2022","journal-title":"Circulation"},{"key":"2026052019382076500_xvag104-B16","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms18081682","article-title":"Sympathetic overactivity in chronic kidney disease: consequences and mechanisms","volume":"18","author":"Kaur","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026052019382076500_xvag104-B17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/ijms22010408","article-title":"Fibrosis in chronic kidney disease: pathogenesis and consequences","volume":"22","author":"Panizo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026052019382076500_xvag104-B18","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026052019382076500_xvag104-B19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","article-title":"Renal-cardiac crosstalk in the pathogenesis and progression of heart failure","volume":"136","author":"Noels","year":"2025","journal-title":"Circ Res"},{"key":"2026052019382076500_xvag104-B20","doi-asserted-by":"publisher","first-page":"H135","DOI":"10.1152\/ajpheart.00908.2024","article-title":"Endothelial dysfunction in chronic kidney disease: a clinical perspective","volume":"329","author":"Cho","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026052019382076500_xvag104-B21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with Type 2 diabetes Mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026052019382076500_xvag104-B22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026052019382076500_xvag104-B23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jacc.2015.12.052","article-title":"Echocardiography criteria for structural heart disease in patients with End-stage renal disease initiating hemodialysis","volume":"67","author":"Hickson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jacc.2014.01.020","article-title":"Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup","volume":"63","author":"Chawla","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes Mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c&lt;7%: results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"2026052019382076500_xvag104-B26","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026052019382076500_xvag104-B29","doi-asserted-by":"publisher","first-page":"sfaf350","DOI":"10.1093\/ckj\/sfaf350","article-title":"SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art","volume":"19","author":"Minutolo","year":"2026","journal-title":"Clin Kidney J"},{"key":"2026052019382076500_xvag104-B30","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag104\/68020595\/xvag104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag104\/68020595\/xvag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag104\/68020595\/xvag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:38:30Z","timestamp":1779320310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag104\/8650697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag104","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,9]]},"article-number":"xvag104"}}